{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T04:09:21Z","timestamp":1777522161330,"version":"3.51.4"},"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T00:00:00Z","timestamp":1495670400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"CTSA,National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH)","award":["UL1 TR000135"],"award-info":[{"award-number":["UL1 TR000135"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0177107","type":"journal-article","created":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T13:30:02Z","timestamp":1495719002000},"page":"e0177107","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["Mycophenolate mofetil for scleroderma-related interstitial lung disease: A real world experience"],"prefix":"10.1371","volume":"12","author":[{"given":"Misbah","family":"Baqir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashima","family":"Makol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas G.","family":"Osborn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian J.","family":"Bartholmai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay H.","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,5,25]]},"reference":[{"issue":"6","key":"ref1","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard.2006.062901","article-title":"Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database","volume":"66","author":"UA Walker","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"ref2","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.autrev.2015.02.002","article-title":"Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?","volume":"14","author":"M Iudici","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"25","key":"ref3","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"DP Tashkin","year":"2006","journal-title":"N Engl J Med"},{"issue":"10","key":"ref4","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1002\/art.30467","article-title":"Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group","volume":"63","author":"D Khanna","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"12","key":"ref5","doi-asserted-by":"crossref","first-page":"947","DOI":"10.7326\/0003-4819-132-12-200006200-00004","article-title":"Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis","volume":"132","author":"B White","year":"2000","journal-title":"Ann Intern Med"},{"issue":"5","key":"ref6","first-page":"1005","article-title":"Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease","volume":"34","author":"D Launay","year":"2007","journal-title":"J Rheumatol"},{"issue":"8","key":"ref7","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/art.38702","article-title":"Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct?","volume":"66","author":"EL Herzog","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"ref8","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/rheumatology\/35.10.989","article-title":"Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients","volume":"35","author":"ET Koh","year":"1996","journal-title":"Br J Rheumatol"},{"issue":"12","key":"ref9","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"RK Hoyles","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"5","key":"ref10","doi-asserted-by":"crossref","first-page":"R124","DOI":"10.1186\/ar2534","article-title":"Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies","volume":"10","author":"C Nannini","year":"2008","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"ref11","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s10067-011-1823-1","article-title":"Effect of mycophenolate sodium in scleroderma-related interstitial lung disease","volume":"30","author":"CP Simeon-Aznar","year":"2011","journal-title":"Clin Rheumatol"},{"issue":"2","key":"ref12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1378\/chest.06-2861","article-title":"Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease","volume":"133","author":"AJ Gerbino","year":"2008","journal-title":"Chest"},{"issue":"10","key":"ref13","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s10067-010-1498-z","article-title":"Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease","volume":"29","author":"A Koutroumpas","year":"2010","journal-title":"Clin Rheumatol"},{"issue":"8","key":"ref14","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/rheumatology\/kei211","article-title":"Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease","volume":"45","author":"SN Liossis","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.rmed.2007.07.021","article-title":"Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease","volume":"102","author":"AC Zamora","year":"2008","journal-title":"Respir Med"},{"issue":"6 Suppl","key":"ref16","doi-asserted-by":"crossref","first-page":"616S","DOI":"10.1378\/chest.128.6_suppl.616S","article-title":"The impact of pulmonary hypertension on survival in patients with idiopathic pulmonary fibrosis","volume":"128","author":"HF Nadrous","year":"2005","journal-title":"Chest"},{"issue":"9","key":"ref17","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.rmed.2008.03.022","article-title":"Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis","volume":"102","author":"SD Nathan","year":"2008","journal-title":"Respir Med"},{"issue":"3","key":"ref18","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/rheumatology\/kel244","article-title":"Mycophenolate mofetil in diffuse cutaneous systemic sclerosis\u2014a retrospective analysis","volume":"46","author":"SI Nihtyanova","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"ref19","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00408-013-9499-8","article-title":"Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study","volume":"191","author":"ST Panopoulos","year":"2013","journal-title":"Lung"},{"issue":"9","key":"ref20","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"DP Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"5","key":"ref21","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3109\/03009742.2015.1023829","article-title":"The effects of mycophenolate mofetil on cytokines and their receptors in pulmonary arterial hypertension in rats","volume":"44","author":"YF Zhang","year":"2015","journal-title":"Scand J Rheumatol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"143637","DOI":"10.1155\/2012\/143637","article-title":"Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis","volume":"2012","author":"A Tzouvelekis","year":"2012","journal-title":"Pulm Med"},{"issue":"2","key":"ref23","first-page":"144","article-title":"Systemic sclerosis-associated interstitial pneumonia: evaluation of pulmonary function over a five-year period","volume":"37","author":"AJ Lopes","year":"2011","journal-title":"J Bras Pneumol"},{"issue":"4","key":"ref24","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/art.22099","article-title":"Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline","volume":"55","author":"SC Plastiras","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"9","key":"ref25","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/art.1780370903","article-title":"Severe restrictive lung disease in systemic sclerosis","volume":"37","author":"VD Steen","year":"1994","journal-title":"Arthritis Rheum"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0177107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T09:42:59Z","timestamp":1540287779000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0177107"}},"subtitle":[],"editor":[{"given":"Shervin","family":"Assassi","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,5,25]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,5,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0177107","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,25]]}}}